000			05596cam a2200421Ii 4500
001			95289
003			ES-MaUEC
005			20230221040152.0
006			m o d
007			cr cnu|||unuuu
008			170131s2017 si a ob 000 0 eng d
020			_a9789811020025 _q(electronic bk.)
020			_a9811020027 _q(electronic bk.)
020			_z9789811020001 _q(print)
020			_z9811020000
035			_a(OCoLC)970693478 _z(OCoLC)971035477 _z(OCoLC)971069251 _z(OCoLC)971219532 _z(OCoLC)971356185 _z(OCoLC)971536865 _z(OCoLC)971593452 _z(OCoLC)974650190 _z(OCoLC)981869187 _z(OCoLC)1005773603 _z(OCoLC)1011795851
040			_aN$T _cN$T _dEBLCP _dGW5XE _dN$T _dIDEBK _dUAB _dNJR _dYDX _dOCLCO _dOCLCF _dOCLCO _dUPM _dOCLCO _dIOG _dESU _dZ5A _dJBG _dIAD _dICW _dICN _dOTZ _dOCLCQ _dVT2 _dOCLCO _dU3W _dES-MaUEC _bspa
050		4	_aRC280.L8 _b2017 EB
245	0	0	_aMolecular targeted therapy of lung cancer _cYuichi Takiguchi, editor.
264		1	_aSingapore _bSpringer International Publishing _c2017
300			_a1 recurso en línea _bilustraciones (algunas a color)
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
504			_aIncluye referencias bibliográficas
505	0		_aPreface; References; Contents; Part I: Diagnosis; Chapter 1: Classification of Adenocarcinoma of the Lung, with a Special Reference to Prognosis; 1.1 Classification of Adenocarcinoma of the Lung in New WHO Classification; 1.1.1 Introduction: Major Changes in the Classification; 1.1.2 Preinvasive Lesions; 1.1.2.1 Atypical Adenomatous Hyperplasia (AAH) (Fig. 1.1); 1.1.2.2 Adenocarcinoma In Situ (AIS) (Fig. 1.2); 1.1.3 Minimally Invasive Adenocarcinoma (MIA) (Fig. 1.4); 1.1.4 Invasive Adenocarcinoma (Fig. 1.3) (Table 1.2); 1.1.4.1 Lepidic Adenocarcinoma (Fig. 1.5).
505	8		_a1.1.4.2 Acinar Adenocarcinoma (Fig. 1.6)1.1.4.3 Papillary Adenocarcinoma (Fig. 1.7); 1.1.4.4 Micropapillary Adenocarcinoma (Fig. 1.8); 1.1.4.5 Solid Adenocarcinoma (Fig. 1.9); 1.1.5 Variants of Adenocarcinoma; 1.1.5.1 Invasive Mucinous Adenocarcinoma (IMA) (Fig. 1.10); 1.1.5.2 Colloid Adenocarcinoma (Fig. 1.11); 1.1.5.3 Fetal Adenocarcinoma (Fig. 1.12); 1.1.5.4 Enteric Adenocarcinoma (Fig. 1.13); References; Chapter 2: Screening Lung Cancer with Low-Dose CT Combined with Molecular Markers; 2.1 Introduction; 2.2 History of Study on Early Detection of Lung Cancer with CT.
505	8		_a2.2.1 Single-Arm Retrospective or Prospective Studies2.2.2 Small-Scale Randomized Studies; 2.3 Major Outcomes of the NLST; 2.3.1 The First Positive Study of a Large-Scale Randomized Study; 2.3.2 Post Hoc Analyses of the NLST; 2.3.3 Implementation of LDCT as a Public Health-Care Program in the USA; 2.4 Future Directions Beyond CT Screening; 2.4.1 Computer-Aided Evaluation of CT Screening; 2.4.2 Molecular Marker-Assisted Lung Cancer Screening with LDCT; 2.5 Conclusion; References; Chapter 3: PET-CT, Bio-imaging for Predicting Prognosis and Response to Chemotherapy in Patients with Lung Cancer.
505	8		_a3.1 Introduction3.2 Prognostic Variables in Patients with Lung Cancer; 3.3 Biological Significance of 18F-FDG-PET; 3.4 Clinical Role of 18F-FDG-PET as a Predictor of Outcome After Chemotherapy; 3.5 False-Positive Findings in 18F-FDG-PET; 3.6 Development of Tumor-Specific PET Tracers; 3.7 Clinical Significance of 18F-FAMT-PET; 3.8 Prognostic Significance of LAT1 Expression; 3.9 Summary and Conclusion; References; Chapter 4: Methods in Molecular Diagnosis; 4.1 Genomic Alterations in Lung Cancer [1]; 4.2 Concept of the Driver Mutations; 4.3 Important Driver Genes.
505	8		_a4.3.1 The mutated Epidermal Growth Factor Receptor (EGFR) Gene4.3.2 The mutated v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Gene; 4.3.3 The Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK)-Fusion Gene; 4.3.4 The mutated BRAF Gene, the ROS1-Fusion Genes, and the RET-Fusion Genes; 4.4 Specimen Used for the Molecular Diagnosis of Lung Cancer; 4.5 Methods; 4.5.1 PCR-Based Methods; 4.5.2 RT-PCR-Based Methods; 4.5.3 Next-Generation Sequencing (NGS); 4.5.4 Utilization of Liquid Biopsy Samples; 4.5.5 FISH (Fluorescent In Situ Hybridization); 4.5.6 Immunohistochemistry (IHC).
520	3		_aThis book discusses the latest molecular targeted therapy of lung cancer including its evaluation and future directions. It clearly illustrates the initial dramatic effectiveness of molecular targeted therapy, recurrence of the disease, overcoming the wide variety of resistance mechanisms using new-generation molecular targeted agents and potential novel approaches. It also outlines the increasing necessity for new diagnostic technology and strategies for managing different adverse effects and novel methods for evaluating effectiveness and safety. Edited and authored by opinion leaders, Molecular Targeted Therapy of Lung Cancer provides a comprehensive overview of the disease and its treatments. It is a valuable resource for graduate students, post-doctoral fellows and faculty staff, as well as researchers involved in clinical and translational research on lung cancer, helping promote new ideas for further advances.
650		7	_aPulmones _xCáncer _2embne _0(OCoLC)fst01767392 _0 _9168954
700	1		_aTakiguchi, Yuichi, _eeditor literario
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-981-10-2002-5 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
988			_aSpringer_Medicine_2017
998			_b02/2018 _dz _e- _zSI
999			_c95289 _d95289 _x1